GLP‑1 caution grows

Glucagon-like peptide-1 drugs help people feel full and eat less, but doctors are warning that taking them without medical supervision can strip away muscle and leave diets nutritionally thin. (obesity.org) Use of the drugs is no longer niche: 12% of U.S. adults told KFF in a poll published November 14, 2025, that they were currently taking a glucagon-like peptide-1 drug for weight loss, diabetes, or another condition. Nearly one in five adults, 18%, said they had taken one at some point. (kff.org) The drugs work in part by slowing how fast food leaves the stomach, which can reduce appetite and blunt blood-sugar spikes after meals. That same stomach-slowing effect can create problems around endoscopy or anesthesia because retained stomach contents can raise aspiration risk. (academic.oup.com) Medical groups moved last year to spell out what supervised use is supposed to look like. A May 30, 2025 clinical advisory from four U.S. nutrition and obesity organizations called for baseline nutrition assessment, management of gastrointestinal side effects, prevention of micronutrient deficiencies, and adequate protein intake plus strength training to preserve lean mass. (obesity.org) That guidance reflected a shift in the conversation from the bathroom scale to body composition. In a 160-person substudy of the SURMOUNT-1 trial, tirzepatide cut body weight by 21.3% over 72 weeks, with about 75% of the weight lost coming from fat mass and 25% from lean mass. (onlinelibrary.wiley.com) Doctors are also warning patients not to treat social media, telehealth questionnaires, or gray-market sellers as substitutes for follow-up care. The Food and Drug Administration says unapproved compounded versions do not undergo the agency’s premarket review for safety, effectiveness, or quality. (fda.gov) The agency has flagged practical risks that have little to do with weight-loss hype and a lot to do with drug handling. It said some compounded injectable glucagon-like peptide-1 drugs arrived warm or with inadequate ice packs, a storage failure that can affect product quality. (fda.gov) Cost is pushing some patients toward shortcuts even as demand rises. In the same KFF poll, 56% of current users said the drugs were difficult to afford, and 14% of people who had ever taken them said they had stopped because of cost. (kff.org) Federal regulators are tightening the backdrop as supplies change. On April 1, 2026, the Food and Drug Administration said the tirzepatide injection shortage had been resolved and reminded compounders that legal exemptions apply only when specific conditions are met. (fda.gov) The message from obesity and nutrition specialists is narrower than the hype around the drugs: the prescription is not the whole treatment. They are telling patients to pair the medication with clinician monitoring, protein intake, resistance exercise, and regular reassessment instead of trying to manage a powerful appetite suppressant alone. (obesity.org)